Akoya Biosciences (AKYA) announced the appointment of Jennifer Kamocsay as General Counsel. Kamocsay will oversee all company legal activities and provide strategic guidance and corporate governance oversight. Kamocsay most recently served as General Counsel of Rubius Therapeutics (RUBY), where she was responsible for overseeing and managing all of the company’s legal affairs.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AKYA:
- Akoya to Report Fourth Quarter and Full Year 2022 Financial Results on March 6th, 2023 and Participate at Two Upcoming Investor Conferences
- Akoya Biosciences initiated with a Buy at UBS
- Akoya Biosciences to present results from spatial multiomics study
- Akoya Biosciences to Present First-of-its-Kind Spatial Multiomics Dataset at 2023 AGBT General Meeting
- Akoya Biosciences participates in a conference call with JPMorgan